The lower limit of detection of the RT-PCR amplification method restricted the analysis of viral isolates. Amplicons containing the NS5B region were generated by reverse transcription and PCR. Genotyping and phenotyping methods

- No viral breakthrough was observed during treatment. BI 207127 is an orally available, reversible, thumb-pocket 1 non-nucleoside inhibitor of the NS5B polymerase region.
- A Chimeric HCV subgenomic replicon was constructed to determine BI 207127 susceptibility was observed among diverse GT-1 and GT-2 NS5B sequences.
- No loss in sensitivity to the NS5B polymerase inhibitor BI-801524 was conferred by GT-1a results containing these mutations in NS5B (Table 2).

Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5 days monotherapy

- The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), October 29–November 2, 2010, Boston, MA, USA

RESULTS

- All resistant variants were tested in GT-1a-infected patients.
- The predominant mutants in treatment follow-up exposed placebo or placebo.
- Longitudinal cloning analysis
- All resistant variants were identified in GT-1a-infected patients.
- The predominant mutants in treatment follow-up exposed placebo or placebo.
- No loss in sensitivity to the NS5B polymerase inhibitor BI-801524 was conferred by GT-1a results containing these mutations in NS5B (Table 2).

Antiviral activity
- Median VL reduction according to HCV subtype (change from baseline) for each dose level with a mean of 43 nM for GT-1a and 17 nM for GT-1b. These values are significantly different between Placebo

- Placebo 100 mg 200 mg 400 mg 800 mg 1,200 mg
- The median VL reduction according to HCV subtype (change from baseline) for each dose level with a mean of 43 nM for GT-1a and 17 nM for GT-1b. These values are significantly different between Placebo

- Placebo 100 mg 200 mg 400 mg 800 mg 1,200 mg
- The median VL reduction according to HCV subtype (change from baseline) for each dose level with a mean of 43 nM for GT-1a and 17 nM for GT-1b. These values are significantly different between Placebo

Phenotyping of NS5B resistant variants

- All resistant variants were tested in GT-1a-infected patients.
- The predominant mutants in treatment follow-up exposed placebo or placebo.
- No loss in sensitivity to the NS5B polymerase inhibitor BI-801524 was conferred by GT-1a results containing these mutations in NS5B (Table 2).

METHODS

- Genotyping and phenotyping methods
- Viral RNA extraction and PCR amplification
- Whole blood was isolated from the plasma of HCV-infected patients at baseline, day 6 and day 14.
- Genotyping
- NS5B was amplified at baseline, day 6 and day 14 for all samples with HCV genotype 1a and 1b.
- Genotyping
- NS5B was amplified at baseline, day 6 and day 14 for all samples with HCV genotype 1a and 1b.
- Genotyping
- NS5B was amplified at baseline, day 6 and day 14 for all samples with HCV genotype 1a and 1b.